MedPath

Assessing Outpatient 'Day Procedure' for Second-trimester Medical Abortion at Two Public Sector Hospitals in Nepal

Phase 4
Completed
Conditions
Abortion in Second Trimester
Interventions
Registration Number
NCT05046041
Lead Sponsor
Gynuity Health Projects
Brief Summary

This study seeks to evaluate the safety, acceptability and feasibility of an outpatient "day procedure" for medical abortion at 13-18 weeks gestation in two public sector facilities. It also seeks to document the roles of health workers in providing services related to later abortion care and to document the costs of this day procedure to the health system.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
120
Inclusion Criteria
  1. Have an ongoing pregnancy of 13-18 weeks gestation
  2. Meet legal criteria to obtain abortion at 13-18 weeks gestation (Legal criteria include pregnancy resulting from rape or incest, fetal malformation and/or if the pregnancy affects the physical or mental health of the woman)
  3. Have access to a phone where she can be reached at the 2-week follow up or willing to return to the clinic for an in-person interview with the research assistant
  4. Be willing to follow study procedures
Exclusion Criteria
  1. Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  2. Any contraindications to vaginal delivery
  3. More than one prior cesarean delivery
  4. Living more than 2 hours away from the hospital

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Mifepristone + MisoprostolMifepristone + Misoprostol200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
Primary Outcome Measures
NameTimeMethod
Proportion of participants with method success on the same day as misoprostol initiation.0 - 48 hours after first dose of mifepristone

Success is defined as expelling fetus and placenta without surgical intervention and return home on the same day

Secondary Outcome Measures
NameTimeMethod
Average pain scores0 - 48 hours after first dose of misoprostol

Severity incidence based on a 0-10 point pain scale

Frequency of individual side effects experienced by participants0 - 48 hours after first dose of misoprostol

Side effects evaluated include diarrhea, nausea, vomiting, fever, chills

Proportion of reported complications0-2 weeks after initial visit

Participants who returned to a health facility for evaluation and management of complications within 2 weeks of taking mifepristone

Average number of total doses of misoprostol0 - 48 hours after first misoprostol dose

Total misoprostol doses administered from induction to delivery of placenta.

Average total hospital admission timeWithin 0 - 48 hours after the second dose of misoprostol

Total hospital admission time, including: 1) total admission time during treatment with misoprostol and abortion recovery 2) Additional hospital time required for the evaluation and management of complications

Average induction-to-abortion interval0 - 48 hours after first misoprostol dose

Time interval from administration of the first misoprostol dose until expulsion of both fetus and placenta

Description of tasks performed by different cadres of study staff0 - 72 hours after receipt of mifepristone

Tasks evaluated include counseling, monitoring vital signs, administering drugs, monitoring woman's condition, post-abortion contraception, managing discharge

Frequency of adverse events0-2 weeks after initial visit

Adverse events include extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, or prolonged hospitalization, any complications (immediate and delayed)

Proportion of satisfied participants2 weeks after initial visit

Participants who report high satisfaction with service

Trial Locations

Locations (2)

Bharatpur Hospital

🇳🇵

Bharatpur, Nepal

Lumbini Provincial Hospital

🇳🇵

Butwāl, Nepal

© Copyright 2025. All Rights Reserved by MedPath